Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - venlafaxine hydrochloride, quantity: 169.8 mg (equivalent: venlafaxine, qty 150 mg) - capsule, modified release - excipient ingredients: gelatin; ethylcellulose; sunset yellow fcf; povidone; magnesium stearate; microcrystalline cellulose; brilliant blue fcf; copovidone; allura red ac; purified talc; colloidal anhydrous silica; titanium dioxide; propylene glycol; ethanol; isopropyl alcohol; shellac; tert-butyl alcohol; sodium hydroxide - apo-venlafaxine xr is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - venlafaxine hydrochloride, quantity: 84.9 mg (equivalent: venlafaxine, qty 75 mg) - capsule, modified release - excipient ingredients: iron oxide black; colloidal anhydrous silica; ethylcellulose; iron oxide red; magnesium stearate; microcrystalline cellulose; povidone; purified talc; titanium dioxide; gelatin; copovidone; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia - blooms the chemist venlafaxine xr is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - venlafaxine hydrochloride, quantity: 169.8 mg (equivalent: venlafaxine, qty 150 mg) - capsule, modified release - excipient ingredients: gelatin; ethylcellulose; sunset yellow fcf; povidone; magnesium stearate; microcrystalline cellulose; brilliant blue fcf; copovidone; allura red ac; purified talc; colloidal anhydrous silica; titanium dioxide; propylene glycol; ethanol; isopropyl alcohol; shellac; tert-butyl alcohol; sodium hydroxide - blooms the chemist venlafaxine xr is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - venlafaxine hydrochloride, quantity: 169.8 mg (equivalent: venlafaxine, qty 150 mg) - capsule, modified release - excipient ingredients: gelatin; ethylcellulose; sunset yellow fcf; povidone; magnesium stearate; microcrystalline cellulose; brilliant blue fcf; copovidone; allura red ac; purified talc; colloidal anhydrous silica; titanium dioxide; propylene glycol; ethanol; isopropyl alcohol; shellac; tert-butyl alcohol; sodium hydroxide - elaxine sr 150 is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - venlafaxine hydrochloride, quantity: 84.9 mg (equivalent: venlafaxine, qty 75 mg) - capsule, modified release - excipient ingredients: iron oxide black; colloidal anhydrous silica; ethylcellulose; iron oxide red; magnesium stearate; microcrystalline cellulose; povidone; purified talc; titanium dioxide; gelatin; copovidone; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia - elaxine sr 75 is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - venlafaxine hydrochloride, quantity: 42.45 mg (equivalent: venlafaxine, qty 37.5 mg) - capsule, modified release - excipient ingredients: microcrystalline cellulose; copovidone; gelatin; magnesium stearate; titanium dioxide; povidone; iron oxide black; iron oxide yellow; colloidal anhydrous silica; purified talc; iron oxide red; ethylcellulose; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia - elaxine sr 37.5 is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - venlafaxine hydrochloride, quantity: 169.8 mg (equivalent: venlafaxine, qty 150 mg) - capsule, modified release - excipient ingredients: gelatin; ethylcellulose; sunset yellow fcf; povidone; magnesium stearate; microcrystalline cellulose; brilliant blue fcf; copovidone; allura red ac; purified talc; colloidal anhydrous silica; titanium dioxide; propylene glycol; ethanol; isopropyl alcohol; shellac; tert-butyl alcohol; sodium hydroxide - sandoz venlafaxine xr is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - venlafaxine hydrochloride, quantity: 84.9 mg (equivalent: venlafaxine, qty 75 mg) - capsule, modified release - excipient ingredients: iron oxide black; colloidal anhydrous silica; ethylcellulose; iron oxide red; magnesium stearate; microcrystalline cellulose; povidone; purified talc; titanium dioxide; gelatin; copovidone; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia - sandoz venlafaxine xr is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - risperidone, quantity: 4 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; indigo carmine aluminium lake; lactose monohydrate; quinoline yellow; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 4000 - treatment of schizophrenia and related psychoses. short-term treatment of acute mania associated with bipolar i disorder. treatment of behavioural disturbances in dementia. treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - risperidone, quantity: 3 mg - tablet, film coated - excipient ingredients: quinoline yellow; lactose monohydrate; magnesium stearate; pregelatinised maize starch; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 4000 - treatment of schizophrenia and related psychoses. short-term treatment of acute mania associated with bipolar i disorder. treatment of behavioural disturbances in dementia. treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).